Day: February 5, 2024

Posted on

Curia Receives 2024 CDMO Leadership Award

Curia recognized for its Service in the CDMO industry

2024 CDMO Leadership Award
Curia Receives 2024 CDMO Leadership Award in the Service category.

ALBANY, N.Y., Feb. 05, 2024 (GLOBE NEWSWIRE) — Curia, a leading contract research, development and manufacturing organization, today announced it has been awarded a 2024 CDMO Leadership Award in the Service category, Small Pharma group. In its 13th year, the awards are presented by Outsourced Pharma and Life Science Leader.

“Curia is honored to receive this award,” said Philip Macnabb, CEO, Curia. “This distinction underscores our commitment to creating value for our customers across all of our R&D and manufacturing offerings, and we are especially appreciative to be acknowledged by the partners we support for that commitment.”

Winners of CDMO Leadership Awards are selected based on market research by Industry Standard Research (“ISR”) to distinguish CDMOs that meet or exceed customer expectations. For the 2024 awards, 98 contract manufacturers were evaluated by 23 performance metrics in ISR’s annual Contract Manufacturing Quality Benchmarking survey. Respondents to the survey only evaluate companies with which they have worked on an outsourced project within the past 18 months. Curia was awarded based on the feedback of respondents in the Small Pharma category.

“Congratulations to our 2024 CDMO Leadership Award winners. By vote of your customers, you are recognized as the best in the global outsourcing development and manufacturing sector of the biopharma industry,” says Louis Garguilo, Chief Editor and Conference Chair, Outsourced Pharma. “Award winners maintained and expanded capabilities and expertise to meet the needs of a diverse customer base; provided the additional quality and reliability so crucial to novel processes and products; and forged the closest relationships with customers. 2023 rang in with many unsettled questions. The 2024 CDMO Leadership Award winners are the support companies that best answered the bell over the past year.”

About Curia
Curia is a Contract Development and Manufacturing Organization (CDMO) with over 30 years of experience, an integrated network of 27 global sites and over 3,500 employees partnering with Biopharmaceutical customers to bring life-changing therapies to market. Our biologics and small molecules offering spans discovery through commercialization, with integrated regulatory and analytical capabilities. Our scientific and process experts and state-of-the-art facilities deliver best-in-class experience across drug substance and drug product manufacturing. From curiosity to cure, we deliver every step to improve patients’ lives. Visit us at curiaglobal.com.

Corporate Contact:
Viana Bhagan
Curia
+1 518 512 2111
corporatecommunications@CuriaGlobal.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/328a3a12-3a66-4a34-bdc8-e5de362efb85

GlobeNewswire Distribution ID 9031149

Posted on

Curia reçoit le CDMO Leadership Award 2024

Curia est ainsi reconnue pour son service dans le secteur des organisations de développement et de fabrication sous contrat

ALBANY, New York, 05 févr. 2024 (GLOBE NEWSWIRE) — Curia, une organisation de développement et de fabrication sous contrat (CDMO) de premier plan, a annoncé aujourd’hui qu’elle avait reçu le CDMO Leadership Award 2024 dans la catégorie Service, groupe Small Pharma. Dans leur 13e année, les prix sont décernés par Outsourced Pharma et Life Science Leader.

« C’est un honneur pour Curia de recevoir ce prix », a déclaré Philip Macnabb, PDG de Curia. « Cette récompense souligne notre engagement à créer de la valeur pour nos clients dans l’ensemble de notre offre de R&D et de fabrication, et nous sommes particulièrement heureux de voir cet engagement reconnu par les partenaires que nous soutenons ».

Les lauréats des CDMO Leadership Awards sont sélectionnés sur la base d’une étude de marché réalisée par Industry Standard Research (« ISR ») afin de reconnaître les CDMO qui répondent aux attentes des clients, ou les dépassent. Pour le prix 2024, 98 fabricants sous contrat ont été évalués selon 23 indicateurs de performance dans l’enquête annuelle d’évaluation comparative de la qualité de la fabrication sous contrat menée par ISR. Les participants à l’enquête ont uniquement évalué les entreprises avec lesquelles ils ont travaillé sur un projet externalisé au cours des 18 derniers mois. Curia a été récompensée sur la base des commentaires des participants dans la catégorie Small Pharma.

« Félicitations aux lauréats du CDMO Leadership Award 2024. Par le vote de vos clients, vous êtes reconnus comme les meilleurs dans le secteur de l’externalisation du développement et de la fabrication de l’industrie biopharmaceutique », déclare Louis Garguilo, rédacteur en chef et président de la conférence, Outsourced Pharma. « Les lauréats ont maintenu et développé leurs capacités et leur expertise afin de répondre aux besoins d’une clientèle diverse ; ils ont fourni la qualité et la fiabilité supplémentaires si cruciales pour les nouveaux processus et produits ; et ils ont forgé les relations les plus étroites avec leurs clients. L’année 2023 a débuté par de nombreuses questions non résolues. Les lauréats du CDMO Leadership Award 2024 sont les entreprises sous-traitantes qui ont le mieux répondu à ces questions au cours de l’année écoulée ».

À propos de Curia
Curia est une organisation de développement et de fabrication sous contrat (CDMO) avec plus de 30 ans d’expérience, un réseau intégré de 27 sites dans le monde et plus de 3 500 collaborateurs travaillant en partenariat avec les clients biopharmaceutiques pour mettre sur le marché des thérapies qui changent la vie. Notre offre de produits biologiques et de petites molécules couvre le cycle complet de la découverte jusqu’à la commercialisation, avec des capacités réglementaires et analytiques intégrées. Nos scientifiques, nos experts en processus et nos installations de pointe apportent une expérience de premier ordre dans la fabrication de substances et de produits pharmaceutiques. De la curiosité au traitement, nous exécutons toutes les étapes pour améliorer la vie des patients. Consultez notre site à l’adresse www.curiaglobal.com.

Contact de l’entreprise :
Viana Bhagan
Curia
+1 518 512 2111
corporatecommunications@CuriaGlobal.com

Une photo accompagnant ce communiqué est disponible à l’adresse suivante : https://www.globenewswire.com/NewsRoom/AttachmentNg/328a3a12-3a66-4a34-bdc8-e5de362efb85

GlobeNewswire Distribution ID 9031542

Posted on

Curia recebe CDMO Leadership Award de 2024

Curia reconhecida pelo seu serviço na indústria de CDMO

ALBANY, N.Y., Feb. 05, 2024 (GLOBE NEWSWIRE) — A Curia, uma organização líder em pesquisa, desenvolvimento e fabricação por contrato, anunciou hoje que recebeu um Prêmio de Liderança CDMO 2024 na categoria de Serviços do grupo Small Pharma. No seu 13º ano, os prêmios são apresentados pela Outsourced Pharma e Life Science Leader.

“A Curia recebe este prêmio com muita honra”, disse Philip Macnabb, CEO da Curia. “Essa distinção ressalta o nosso compromisso de criar valor para nossos clientes em todas as nossas ofertas de P&D e fabricação, e somos especialmente gratos por sermos reconhecidos pelos parceiros que apoiamos com a nossa dedicação.”

Os vencedores do CDMO Leadership Awards são selecionados com base nas pesquisas de mercado da Industry Standard Research (“ISR”) para homenagear as CDMOs que atendam ou excedam as expectativas dos clientes. Para as premiações de 2024, 98 fabricantes contratados foram avaliados com 23 métricas de desempenho na pesquisa anual de Benchmarking de Qualidade de Fabricação por Contrato da ISR. Os participantes da pesquisa avaliam apenas as empresas com as quais trabalharam em um projeto terceirizado nos últimos 18 meses. A Curia foi premiada com base no feedback dos participantes na categoria Small Pharma.

“Parabéns aos vencedores do Prêmio de Liderança CDMO 2024. Com o voto dos seus clientes, vocês foram reconhecidos como o melhor no setor global de desenvolvimento e fabricação terceirizada da indústria biofarmacêutica”, disse Louis Garguilo, Editor-Chefe e Presidente de Conferência da Outsourced Pharma. “Os vencedores do prêmio mantiveram e expandiram sua capacidade e conhecimento para atender às necessidades de uma base de clientes diversificada; forneceram a qualidade e confiabilidade adicionais tão cruciais para os novos processos e produtos; e estabeleceram relações mais próximas com os clientes. 2023 trouxe à tona muitas questões não resolvidas. Os vencedores do CDMO Leadership Award de 2024 são as empresas que mais deram suporte no ano passado.”

Sobre a Curia
A Curia é uma Organização de Desenvolvimento e Fabricação por Contratos (CDMO) com mais de 30 anos de experiência, uma rede integrada de 27 locais em todo o mundo e mais de 3.500 funcionários em parcerias com clientes biofarmacêuticos para lançar no mercado terapias que mudam a vida. Nossa oferta de produtos biológicos e pequenas moléculas abrange a descoberta através da comercialização, com capacidades regulatórias e analíticas integradas. Nossos especialistas científicos e de processos, e instalações de última geração oferecem a melhor experiência em fabricação de medicamentos e produtos farmacêuticos. Da curiosidade à cura, proporcionamos todas as etapas para a melhoria da vida dos pacientes. Visite-nos em curiaglobal.com.

Contato Corporativo:
Viana Bhagan
Curia
+1 (518) 512 2111
corporatecommunications@CuriaGlobal.com

Foto deste comunicado disponível em https://www.globenewswire.com/NewsRoom/AttachmentNg/328a3a12-3a66-4a34-bdc8-e5de362efb85

GlobeNewswire Distribution ID 9031542

Posted on

Researchers at KFSH&RC & KAUST Discover Gene Responsible for Reproduction of the Most Dangerous Malaria Strain

Researchers at KFSH&RC & KAUST Discover Gene Responsible for Reproduction of the Most Dangerous Malaria Strain
King Faisal Specialist Hospital and Research Center – Riyadh

RIYADH, Saudi Arabia, Feb. 05, 2024 (GLOBE NEWSWIRE) — In a major scientific breakthrough, a research team from King Faisal Specialist Hospital and Research Centre (KFSH&RC), in collaboration with King Abdullah University of Science and Technology (KAUST), working alongside researchers from the UK, the US, and India, discovered a vital gene instrumental in combating malaria. This gene, termed PfAP2-MRP, is essential in the replication process of Plasmodium falciparum, the parasite that causes the most lethal strain of malaria.

Advanced laboratory techniques enabled the researchers to inhibit the PfAP2-MRP gene, revealing its critical role in the malaria parasite’s life cycle within red blood cells. This inhibition significantly disrupts the parasite’s ability to reproduce, reducing the severity of the disease’s symptoms and curbing its spread. This discovery is particularly impactful as it addresses Plasmodium falciparum malaria, which claims over half a million lives annually.

Dr. Ashraf Dada, Chairman of the Department of Pathology and Laboratory Medicine at King Faisal Specialist Hospital and Research Centre in Jeddah and the lead researcher, stated: “This discovery paves the way for the development of more effective treatments for the deadliest malaria strain, Plasmodium falciparum.” Also, this study enhances the scientific community’s understanding of the disease’s progression and its interaction with the human immune system, thereby strengthening efforts to combat this widespread malaria parasite prevalent in Africa.

Furthermore, the research demonstrated that the PfAP2-MRP gene regulates the production of genetically diverse protein receptors, allowing the parasite to evade the host’s immune system. This mechanism plays a significant role in the global spread of malaria and underscores the gene’s importance in developing future therapeutic strategies.

Published in the prestigious journal “Nature” this noteworthy study is part of a close collaboration between KFSH&RC and KAUST to engage in innovative research activities aimed at not only improving the diagnosis of microbes, bacteria, and parasites, but also underscores a global effort to combat pathogens and improve human health.

King Faisal Specialist Hospital and Research Centre stands among the global leaders in providing specialized healthcare, driving innovation, and serving as an advanced medical research and education hub. Through strategic partnerships with prominent local, regional, and international institutions, the hospital is dedicated to advancing medical technologies and elevating the standards of healthcare worldwide.

About King Faisal Specialist Hospital & Research Centre (KFSH&RC):

King Faisal Specialist Hospital & Research Centre (KFSH&RC) stands as a leading healthcare institution in the Middle East, envisioned to be the optimal choice for every patient seeking specialized healthcare. The hospital boasts a rich history in the treatment of cancers, cardiovascular diseases, organ transplantation, neurosciences, and genetics.

In 2023, “Brand Finance” ranked King Faisal Specialist Hospital & Research Centre as the top academic medical centre in the Middle East and Africa, and among the top 20 globally. Additionally, in 2022, it was recognized as one of the leading global healthcare providers by Newsweek magazine.

As part of Saudi Vision 2030, a royal decree was issued on December 21, 2021, to transform the hospital into an independent, non-profit, government-owned entity, paving the way for a comprehensive transformation program aimed at achieving global leadership in healthcare through excellence and innovation.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/38b3fbef-fece-4a76-b326-2d57ab1b16ba

CONTACT INFORMATION 

For more information please contact:

Mr. Essam Al-Zahrani, Media Affairs Head, 0555254429

Mr. Abdullah Al-Awn, Media Coordination Officer, 0556294232

GlobeNewswire Distribution ID 9031968

Posted on

‫باحثون في “التخصصي” وجامعة “كاوست” يكتشفون جينًا مسؤولاً عن تكاثر أخطر أنواع الملاريا

Researchers at KFSH&RC & KAUST Discover Gene Responsible for Reproduction of the Most Dangerous Malaria Strain
King Faisal Specialist Hospital and Research Center – Riyadh

الرياض, Feb. 05, 2024 (GLOBE NEWSWIRE) —

اكتشف باحثون بمستشفى الملك فيصل التخصصي ومركز الأبحاث، بالتعاون مع جامعة الملك عبدالله للعلوم والتقنية “كاوست”، وباحثون من بريطانيا وأمريكا والهند؛ جيناً مسؤولا عن تكاثر طفيليات الملاريا المتصورة المنجلية داخل كريات الدم الحمراء، وبتعطيل عمله تتوقف الطفيليات عن التكاثر بالشكل المعتاد، مما يؤدي إلى تخفيف أعراض المرض والحد من انتشار عدوى أشرس أنواع الملاريا التي تفتك بأكثر من نصف مليون إنسان سنويا.

وتمكن الباحثون من تحقيق هذا الاكتشاف باستخدام تقنيات مخبرية متقدمة في فحص وتحديد جزيئات وجينات البروتينات المشاركة في دورة طُفيل المتصور المنجلي، حيث تم من خلالها إيقاف عمل جين يُدعى PfAP2-MRP، وهو ما أسهم في إثبات أن طفيليات الملاريا لا تستطيع التكاثر داخل خلايا الدم الحمراء بالشكل المعتاد، كما يتعطل نشاطها وخروجها بشكل ملحوظ من داخل خلية الدم الحمراء المصابة جرّاء تعطل عمل هذا الجين، الأمر الذي يقلل بشكل كبير من اختراق خلايا بشرية جديدة في الدم، مما يسهم في تقليل أعراض المرض وكذلك الحد من انتشار العدوى بين الأفراد.

وقال الدكتور أشرف دادا، رئيس قسم علم الأمراض والطب المخبري في مستشفى الملك فيصل التخصصي ومركز الأبحاث بجدة، والباحث الرئيسي” إن الاكتشاف يمهد الطريق لابتكار أدوية ذات فعالية أكبر لعلاج الملاريا المتصورة المنجلية الذي يُعد الأخطر بين أقرانه“، موضحاً أن البحث يُقدم للمجتمع العلمي فهماً أعمق لكيفية تطور المرض، وآلية تجاوبه مع الجهاز المناعي البشري، مما يُعزز جهود مكافحة نوع الطفيليات المسببة للملاريا الأشد فتكاً والأكثر انتشاراً في القارة الأفريقية.

كما أثبت الباحثون أن الجين PfAP2-MRP يتحكم في الجينات التي تستخدمها طفيليات المتصورة المنجلية في تكوين مستقبلات بروتينية جديدة مختلفة في تركيبها الجيني تتحايل على الأجسام المضادة التي كوّنها الجهاز المناعي لجسم المصاب، لتصبح عديمة الجدوى، ما يتسبب بمعضلة مسؤولة عن انتشار الملاريا في العالم.

وجاءت هذه الدراسة المنشورة بمجلة نيتشر “Nature” الرائدة في مجال العلوم، ضمن تعاون بين “التخصصي” و “كاوست”؛ لإجراء أبحاث تسهم في اكتشاف وسائل مبتكرة لتحسين طريقة تشخيص الميكروبات والجراثيم والطفليات بشكل عام، وكذلك الوقاية والعلاج من الأمراض التي تسبب بها؛ بهدف محاربة الأمراض المعدية والحد من انتشارها.

ويُعد مستشفى الملك فيصل التخصصي ومركز الأبحاث من بين الأبرز عالميًا في تقديم الرعاية الصحية التخصصية، ورائدًا في الابتكار، ومركزًا متقدمًا في البحوث والتعليم الطبي، كما يسعى لتطوير التقنيات الطبية، والارتقاء بمستوى الرعاية الصحية على مستوى العالم، وذلك بالشراكة مع كبرى المؤسسات المحلية والإقليمية والدولية لتحقيق خدمة عالمية المستوى في المجالات السريرية والبحثية والتعليمية.

نبذة عن مستشفى الملك فيصل التخصصي ومركز الأبحاث:

يُعد مستشفى الملك فيصل التخصصي ومركز الأبحاث (KFSH&RC) أحد المؤسسات الصحية في الشرق الأوسط، وتتمثل رؤيته في أن يكون الخيار الأمثل لكل مريض في مجال تقديم الرعاية الصحية التخصصية، حيث يمتلك المستشفى تاريخاً حافلاً في علاج الأورام وأمراض القلب والأوعية الدموية، وزراعة الأعضاء، علوم الأعصاب، وعلم الوراثة.

وخلال العام 2023، صنفت منظمة “Brand Finance” مستشفى الملك فيصل التخصصي ومركز الأبحاث المركز الطبي الأكاديمي الأفضل في منطقة الشرق الأوسط وأفريقيا، ومن بين أفضل 20 مركزًا عالميًا. كما صُنف في العام 2022، ضمن مقدمي الرعاية الصحية الرائدين في جميع أنحاء العالم من قبل مجلة نيوزويك.

كجزء من رؤية السعودية 2030 وبرامجها، صدر في 21 ديسمبر 2021 أمر ملكي يقضي بتحويل المستشفى إلى مؤسسة مستقلة ذات طبيعة خاصة غير هادفة للربح ومملوكة للحكومة، في خطوة مهدت لانطلاق برنامج تحول شامل يستهدف تحقيق الريادة في مجال الرعاية الصحية على الصعيد العالمي من خلال التميز والابتكار.

https://www.globenewswire.com/NewsRoom/AttachmentNg/38b3fbef-fece-4a76-b326-2d57ab1b16ba

لمزيد من المعلومات، يرجى التواصل مع مدير الشؤون الإعلامية في المستشفى الأستاذ عصام الزهراني جوال: 0555254429 للتنسيقات الإعلامية، يرجى التواصل مع مسؤول التنسيقات الإعلامية الأستاذ عبدالله العون جوال: 0556294232

GlobeNewswire Distribution ID 9031968

Posted on

Nocturne Acquisition Corporation Announces Postponement of Extraordinary General Meeting

SANTA ANA, CA / ACCESSWIRE / February 5, 2024 / Nocturne Acquisition Corp. (NASDAQ:MBTCU) (the "Company"), announced today that the Board of Directors has voted in favor of a second postponement of the meeting date for the Extraordinary General Meeting that was to be held on January 30, 2024 for shareholders to vote on the proposed business combination with Cognos Therapeutics, Inc. The Extraordinary General Meeting that was postponed until February 6, 2024 has been postponed further and will now be held virtually on February 27, 2024 at 9:00 a.m. Eastern Time. The Company plans to continue to solicit proxies from shareholders during the period prior to the Extraordinary General Meeting. The record date for the Extraordinary General Meeting remains the close of business on December 29, 2023. No changes have been made in the proposals to be voted on by the shareholders at the postponed meeting. Shareholders who have previously submitted their proxy or otherwise voted and who do not want to change their vote need not take any action. Stockholders as of the record date may vote, even if they have subsequently sold their shares. The deadline by which shareholders must exercise their redemption rights in connection with the Extraordinary General Meeting has been extended to two business days prior to the second postponed meeting.

About Nocturne Acquisition Corp.

The Company is a blank check company organized for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses or entities. While the Company may pursue an acquisition opportunity in any industry or sector, the Company focuses its search for targets bringing to market disruptive technologies in the blockchain/crypto and artificial intelligence technology sectors. Equity value of potential targets is expected to be in the $300 million to $1 billion USD range.

Cautionary Note Regarding Forward-Looking Statements

Statements contained in this press release that are not historical facts may be forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements generally relate to future events or the Company’s future financial or operating performance. In some cases, you can identify forward-looking statements because they contain words such as "may," "will," "should," "expects," "plans," "anticipates," "could," "intends," "target," "projects," "contemplates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these words or other similar terms or expressions that concern the Company’s expectations, strategy, plans or intentions. . Such forward-looking statements do not constitute guarantees of future performance and are subject to a variety of risks and uncertainties. The Company does not undertake any obligation to update forward-looking statements as a result of new information, future events or developments or otherwise.

Additional Information and Where to Find It

A full description of the terms of that certain Agreement and Plan of Merger and Reorganization, dated December 30, 2022, by and among Nocturne, Cognos, and Nocturne Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Nocturne, in connection with the proposed Merger is provided in the definitive Registration Statement which includes a prospectus with respect to the combined company’s securities to be issued in connection with the Merger and a proxy statement with respect to the Extraordinary General Meeting to vote on the Merger. The definitive proxy statement/prospectus included in the Registration Statement has been mailed to stockholders of Nocturne as of the record date of December 29, 2023. Stockholders are also able to obtain a copy of the Registration Statement, including the proxy statement/prospectus, and other documents filed with the SEC without charge, by directing a request to Nocturne Acquisition Corporation, P.O Box 25739, Santa Ana, CA 92799, Attention Thomas Ao. The preliminary and definitive proxy statement/prospectus included in the Registration Statement can also be obtained, without charge, at the SEC’s website (www.sec.gov).

Participants in Solicitation

Nocturne, Cognos and their respective directors and officers may be deemed to be participants in the solicitation of proxies from Nocturne’s stockholders in connection with the proposed business combination. Information about Nocturne’s directors and executive officers and their ownership of Nocturne’s securities is set forth in Nocturne’s filings with the SEC. Additional information regarding the interests of those persons and other persons who may be deemed participants in the proposed business combination may be obtained by reading the Registration Statement.

MBTC Company/Media Contact:

investors@nocturnecorp.com
media@nocturnecorp.com

MBTC Investor Relations Contact:

Chris Tyson/Doug Hobbs
MZ SPAC Investor Relations
(949) 491-8235
MBTC@mzgroup.us

SOURCE: Nocturne Acquisition Corporation

View the original press release on accesswire.com